News and Analysis | Published:

Alzheimer amyloid hypothesis lives on

Nature Reviews Drug Discovery volume 16, pages 35 (2017) | Download Citation

Despite the failure of Eli Lilly's anti-amyloid antibody solanezumab in its latest phase III trial for Alzheimer disease, a bulging pipeline of amyloid-modulating candidates and novel clinical trial strategies still hold promise.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Asher Mullard in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing